Showing 1–9 of 9 · Clinical trials & life sciences
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Parent Roche (ROG.SW) group FY2025 revenue CHF 61.52bn (+2.0%); core operating margin 35.5%; net income CHF 13.80bn.
Diagnostics division sales CHF 13.85bn (+2% at constant exchange rates).
FY2025 revenue $16.31bn (+5.9%); operating margin 13.4%; net income $1.36bn.
Cash $1.98bn; debt $15.72bn.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Part of Dassault Systèmes (DSY.PA).
Latest full-year results not yet captured by HSH.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
FY2025 revenue $44.56bn (+3.9%); operating margin 17.4%; net income $6.70bn.
Cash $9.85bn; debt $39.38bn.
FY2026 revenue $3.20bn (+16.3%); operating margin 28.7%; net income $908.9m.
No debt; $6.56bn cash and short-term investments.
Listed (MDRX).
Latest full-year results not yet captured by HSH.